Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.58 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL9330654 | 0.98 | FFAR1 (0.59) | FFAR1KEAP1PTGS1PTGS2LMNA | |
| SCHEMBL25146556 | 0.94 | FFAR1 (0.67) | FFAR1KEAP1PTGS1PTGS2LMNA | |
| SCHEMBL765464 | 0.90 | HSD17B10 (0.61) | FFAR1KEAP1PTGS1PTGS2LMNA | |
| SCHEMBL8959741 | 0.89 | MAPT (0.59) | FFAR1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL27824740 | 0.88 | PTGS1 (0.53) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL764976 | 0.87 | MAPT (0.62) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL10442968 | 0.86 | PTGS1 (0.53) | FFAR1KEAP1PTGS1PTGS2LMNA | |
| SCHEMBL5196414 | 0.86 | ALDH1A1 (0.59) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL104462 | 0.86 | FFAR1 (0.59) | FFAR1KEAP1LMNAALDH1A1NPSR1 | |
| SCHEMBL25146537 | 0.86 | FFAR1 (0.56) | FFAR1PTGS1PTGS2LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119493348-A | Photoresist stripping liquid and preparation method and application thereof | 福建泓光半导体材料有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-114195633-A | Synthesis method of ibuprofen impurity F | 浙江新和成股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-108181407-B | Method for detecting impurity F in ibuprofen raw material | 扬子江药业集团南京海陵药业有限公司 | 2021-01-19 | — | — | CN | claimed |
| US-20160231323-A1 | PROTECTION OF TCR SIGNALING CHAINS IN CANCER PATIENTS AND ENHANCEMENT OF CAR-T CELL THERAPY | Batu Biologics, Inc. (US) | 2016-08-11 | — | — | US | claimed |
| US-20140030323-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | TIARA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | claimed |
| CN-102716069-A | Injection liquid containing ibuprofen and preparation process of injection liquid | WUXI KFT PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-10-10 | — | — | CN | claimed |
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2012-02-23 | — | — | US | claimed |
| US-20110244045-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | TIARA PHARMACEUTICALS ,INC. (US) | 2011-10-06 | — | — | US | claimed |
| EP-1898930-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | Dynamis Therapeutics, Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2006138609-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | DYNAMIS THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| US-6416772-B1 | Topical dermal anaesthetic | PATTERSON, RICHARD | 2002-07-09 | — | — | US | claimed |
| EP-0253083-B1 | Topical vaginal use of lysine p-isobutylphenylpropionate in antiinflammatory treatment | LISAPHARMA SPA (IT) | 1994-08-31 | — | — | EP | claimed |
| EP-0374850-B1 | Method for preparing alpha-(4-isobutylphenyl)propionic acid or its precursor | NIPPON PETROCHEMICALS CO LTD (JP) | 1994-03-09 | — | — | EP | claimed |
| EP-0194693-B1 | POLYPRENYL COMPOUNDS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | Eisai Co., Ltd. (JP) | 1989-07-26 | — | — | EP | claimed |
| EP-0194693-A1 | Polyprenyl compounds, processes for preparing them, and pharmaceutical composition containing them | Eisai Co., Ltd. (JP) | 1986-09-17 | — | — | EP | claimed |
| EP-0052909-B1 | DERIVATIVE OF ALFA-MERCAPTOPROPIONILGLICINE HAVING THERAPEUTICAL ACTIVITY, PROCESS FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS | Real S.a.s. di Alberto Reiner & C. (IT) | 1985-04-10 | — | — | EP | claimed |
| EP-0052910-B1 | DERIVATIVE OF N-ACETILCYSTEINE HAVING THERAPEUTICAL ACTIVITY, PROCESS FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS | Real S.a.s. di Alberto Reiner & C. (IT) | 1985-04-10 | — | — | EP | claimed |
| US-4341798-A | ANTIINFLAMMATORY AGENT | LABORATORI PROPHIN S.P.A. (IT) | 1982-07-27 | — | — | US | claimed |
| EP-0052910-A1 | Derivative of N-acetilcysteine having therapeutical activity, process for its preparation and related pharmaceutical compositions | Real S.a.s. di Alberto Reiner & C. (IT) | 1982-06-02 | — | — | EP | claimed |
| EP-0052909-A1 | Derivative of alfa-mercaptopropionilglicine having therapeutical activity, process for its preparation and related pharmaceutical compositions | Real S.a.s. di Alberto Reiner & C. (IT) | 1982-06-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030323-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | IL6, IL1B, NACA | FFAR1 962/4885KEAP1 559/4885PTGS1 28/4885 |
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | GRM6, GRM5, GRM7 | FFAR1 1932/4885KEAP1 1217/4885PTGS1 1096/4885 |
| US-20110244045-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | IL6, IL1B, NACA | FFAR1 962/4885KEAP1 559/4885PTGS1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.